{"disease":{"id":"temozolomide","name":"temozolomide"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05512481","title":"Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT03079440","title":"TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT06279767","title":"Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":27,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT03763422","title":"Trial in Low Grade Glioma Patients: Wait or Treat","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}